Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Japanese shares end higher as vaccine progress spurs recovery bets

05/28/2021 | 03:04am EDT

TOKYO, May 28 (Reuters) - Japanese shares ended higher on Friday, as investors swooped on stocks related to the sell-off prompted by MSCI's reshuffle in the previous session, while a steady vaccine rollout whetted risk appetite on hopes of a swift economic recovery.

The Nikkei share average rose 2.10% to 29,149.41, closing above the 29,000 level for the first time since May 10, while the broader Topix gained 1.91% to 1,947.44.

The Nikkei posted a weekly gain of 2.94%, while the Topix closed the week 2.24% higher.

"The rise is too much today and the gains are not reflecting the fundamental strength of the Japanese markets," Shuji Hosoi, senior strategist at Daiwa Securities, said.

"This is a rebound from yesterday's sell-offs that were related to MSCI's regular reshuffle as well as profit-taking towards the end of the month."

The Nikkei snapped a five-day winning run in the previous session, with a daily turnover swelling to the highest in more than three years, as 29 names were dropped from the MSCI's main index.

Rollouts of COVID-19 vaccines have contributed to positive sentiment as investors hope a steady vaccination drive can help accelerate economic recovery, market participants said.

The gains were led by cyclical shares, with nonferrous metals makers, steel makers and machinery makers gaining the most among the 33 sub-indexes of the main bourse.

Railway-related stocks also advanced, with Central Japan Railway, the operator of the bullet trains connecting Tokyo and Osaka, gaining 2.52% and East Japan Railway rising 2.02%.

The stocks that gained the most among the top 30 core Topix names were SoftBank Group up 3.66 %, followed by Shin-Etsu Chemical, rising 3.65%.

Kao Corp, which lost 1.39%, was the worst performer among the Topix 30, followed by Takeda Pharmaceutical falling 1.21%.

(Reporting by Junko Fujita, Editing by Sherry Jacob-Phillips)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
CENTRAL JAPAN RAILWAY COMPANY -1.00% 15855 End-of-day quote.8.67%
DAIWA SECURITIES GROUP INC. 0.00% 574 End-of-day quote.22.13%
EAST JAPAN RAILWAY COMPANY -2.23% 7280 End-of-day quote.5.74%
KAO CORPORATION -1.32% 6574 End-of-day quote.-17.52%
NIKKEI 225 -1.80% 27283.59 Real-time Quote.-0.59%
SHIN-ETSU CHEMICAL CO., LTD. -0.36% 17750 End-of-day quote.-1.61%
SOFTBANK GROUP CORP. -2.61% 6837 End-of-day quote.-15.15%
TAKEDA PHARMACEUTICAL COMPANY LIMITED -1.97% 3682 End-of-day quote.-1.94%
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
07/30TAKEDA PHARMACEUTICAL : Summary of Financial Statements for the Three-month Peri..
PU
07/30TAKEDA PHARMACEUTICAL : Q1 Core EPS Drops, Revenue Rises
MT
07/30Takeda Pharmaceutical's First-Quarter Net Profit More Than Doubled
DJ
07/30TAKEDA PHARMACEUTICAL : Summary of Financial Statements for the Three-month Peri..
PU
07/30TAKEDA PHARMACEUTICAL : Delivers Solid First Quarter FY2021 Results, Positioning..
BU
07/30Takeda Pharmaceutical Company Limited Provides Dividend Guidance for the Seco..
CI
07/30Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Year..
CI
07/30Takeda Pharmaceutical Company Limites Announces Unaudited Consolidated Earnin..
CI
07/29TAKEDA PHARMACEUTICAL : U.S. Food and Drug Administration Grants Breakthrough Th..
AQ
07/29TAKEDA PHARMACEUTICAL : and Frazier Healthcare Partners Announce Collaboration t..
PU
More news
Financials
Sales 2022 3 356 B 30 590 M 30 590 M
Net income 2022 303 B 2 765 M 2 765 M
Net Debt 2022 3 089 B 28 162 M 28 162 M
P/E ratio 2022 19,1x
Yield 2022 4,89%
Capitalization 5 778 B 52 641 M 52 671 M
EV / Sales 2022 2,64x
EV / Sales 2023 2,52x
Nbr of Employees 47 099
Free-Float 99,3%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | 4502 | JP3463000004 | MarketScreener
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 3 682,00 JPY
Average target price 4 898,00 JPY
Spread / Average Target 33,0%
EPS Revisions
Managers and Directors
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Mwana Lugogo Chief Ethics & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED-1.94%52 641
JOHNSON & JOHNSON9.42%453 313
ROCHE HOLDING AG13.38%337 105
PFIZER, INC.16.30%239 637
NOVARTIS AG0.28%225 343
ELI LILLY AND COMPANY44.22%221 348